Phase I Clinical Study of SHR-5495 in the Treatment of Patients With Advanced Malignant Tumors

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study is an open, multicenter, dose-increasing/dose-expanding/efficacy expanding Phase I clinical study aimed at evaluating the tolerance, safety, PK, PD, and immunogenicity of SHR-5495 in the treatment of advanced malignant tumor patients, and preliminarily observing its anti-tumor efficacy. The entire study was divided into three stages: dose escalation, dose extension, and efficacy extension.

Research Team

Eligibility Criteria

Inclusion Criteria

Your ECOG score must be between 0 and 1.

You are between 18 and 70 years of age, gender notwithstanding.

You have a pathologically confirmed advanced malignant tumor that has not responded to conventional treatment approaches or lacks an efficient standard treatment option.

See 6 more